# Immix Biopharma, Inc.: overview

IMMX · Nasdaq · CIK 1873835 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/immx.md) · [Financials](/companies/immx/financials.md) · [Filings](/companies/immx/filings.md) · [Insiders](/companies/immx/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.24)](/filings/0001493152-25-021325.md) | not reported | [(0.15)](/filings/0001493152-26-021764.md) | [(0.22)](/filings/0001493152-26-036643.md) | [(0.24)](/filings/0001493152-25-021325.md) | not reported | [(0.18)](/filings/0001493152-26-021764.md) | [(0.18)](/filings/0001493152-26-036643.md) |
| Free cash flow | $m | [(4.3) d](/filings/0001493152-25-021325.md) | [(2.0) d](/filings/0001493152-26-013298.md) | [(1.8)](/filings/0001493152-26-021764.md) | [(5.4) d](/filings/0001493152-26-036643.md) | [(6.3) d](/filings/0001493152-25-021325.md) | [(11.2) d](/filings/0001493152-26-013298.md) | [(9.9)](/filings/0001493152-26-021764.md) | [(11.8) d](/filings/0001493152-26-036643.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(6.64)](/filings/0001493152-22-007921.md) | [(0.59)](/filings/0001493152-24-011975.md) | [(0.89)](/filings/0001641172-25-000387.md) | [(0.76)](/filings/0001493152-26-013298.md) | [(0.89)](/filings/0001493152-26-013298.md) |
| Free cash flow | $m | [(1.6)](/filings/0001493152-23-009091.md) | not reported | [(11.4)](/filings/0001641172-25-000387.md) | [(15.8)](/filings/0001493152-26-013298.md) | [(24.7)](/filings/0001493152-26-013298.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/immx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $100.8m | 9,783,192 |  | Not compared |
| [Saturn V Capital Management LP](/funds/1964437.md) | 2026-06-30 | $48.0m | 4,658,429 |  | Added +964,844 |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $43.7m | 4,802,002 |  | Not compared |
| [EVENTIDE ASSET MANAGEMENT, LLC](/funds/1442891.md) | 2026-06-30 | $40.1m | 3,891,019 |  | Added +1,342,000 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $30.9m | 2,996,935 |  | Added +2,805,025 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $30.8m | 2,989,972 |  | Added +2,521,595 |
| [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $28.6m | 2,775,000 |  | New +2,775,000 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $25.8m | 2,507,122 |  | Added +719,128 |
| [Opaleye Management Inc.](/funds/1595855.md) | 2026-06-30 | $24.2m | 2,345,000 |  | New +2,345,000 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $21.3m | 2,066,426 |  | Added +316,226 |

## Recent filings

[All 243 filings](/companies/immx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-30 | 17:10 ET | [8-K](/filings/0001493152-26-045143.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-045143 |
| 2026-09-29 | 07:00 ET | [8-K](/filings/0001493152-26-044761.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-044761 |
| 2026-08-07 | 17:05 ET | [10-Q](/filings/0001493152-26-036643.md) | Quarterly report, period 2026-06-30 | 0001493152-26-036643 |
| 2026-07-20 | 06:05 ET | [8-K](/filings/0001493152-26-033829.md) | 8.01 Other events | 0001493152-26-033829 |
| 2026-05-29 | 17:10 ET | [8-K](/filings/0001493152-26-026431.md) | 5.07 Shareholder vote results | 0001493152-26-026431 |
| 2026-05-21 | 17:28 ET | [8-K](/filings/0001493152-26-024872.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-024872 |
| 2026-05-21 | 06:04 ET | [8-K](/filings/0001493152-26-024707.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-024707 |
| 2026-05-07 | 17:17 ET | [10-Q](/filings/0001493152-26-021764.md) | Quarterly report, period 2026-03-31 | 0001493152-26-021764 |
| 2026-04-06 | 16:37 ET | [DEF 14A](/filings/0001493152-26-015320.md) | Proxy statement, period 2026-04-06 | 0001493152-26-015320 |
| 2026-03-30 | 17:39 ET | [8-K](/filings/0001493152-26-013663.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-013663 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-012714.md), filed Mar 25, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1873835
- Tickers: IMMX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:28 ET. No prices; not investment advice.